467 related articles for article (PubMed ID: 25083076)
1. Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu IL; Brunt EM
World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
[TBL] [Abstract][Full Text] [Related]
2. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
3. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
Giashuddin S; Alawad M
Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
[TBL] [Abstract][Full Text] [Related]
5. Pathology of nonalcoholic steatohepatitis.
Brunt EM
Hepatol Res; 2005 Oct; 33(2):68-71. PubMed ID: 16214395
[TBL] [Abstract][Full Text] [Related]
6. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
Bedossa P; Patel K
Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
[TBL] [Abstract][Full Text] [Related]
7. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
Kleiner DE; Makhlouf HR
Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
[TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
10. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Role of Liver Biopsy in Non-alcoholic Fatty Liver Disease.
Arab JP; Barrera F; Arrese M
Ann Hepatol; 2018 Oct; 17(6):899-902. PubMed ID: 30600304
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Brown GT; Kleiner DE
Metabolism; 2016 Aug; 65(8):1080-6. PubMed ID: 26775559
[TBL] [Abstract][Full Text] [Related]
16. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
Drescher HK; Weiskirchen S; Weiskirchen R
Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
[TBL] [Abstract][Full Text] [Related]
17. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
[TBL] [Abstract][Full Text] [Related]
18. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease.
Khov N; Sharma A; Riley TR
World J Gastroenterol; 2014 Jun; 20(22):6821-5. PubMed ID: 24944472
[TBL] [Abstract][Full Text] [Related]
19. The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease.
Isabela Andronescu C; Roxana Purcarea M; Aurel Babes P
J Med Life; 2018; 11(3):243-246. PubMed ID: 30364513
[TBL] [Abstract][Full Text] [Related]
20. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
[No Abstract] [Full Text] [Related]
[Next] [New Search]
